Tigecycline to treat Stenotrophomonas maltophilia ventilator‐associated pneumonia in a trauma intensive care unit as a result of a drug shortage: A case series
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Tigecycline to treat
Stenotrophomonas maltophilia
ventilator‐associated pneumonia in a trauma intensive care unit as a result of a drug shortage: A case series
Authors
Keywords
-
Journal
JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS
Volume -, Issue -, Pages -
Publisher
Wiley
Online
2020-05-15
DOI
10.1111/jcpt.13158
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Efficacy and safety of high-dose tigecycline for the treatment of infectious diseases
- (2019) Jinhong Gong et al. MEDICINE
- Evaluation of Trimethoprim/Sulfamethoxazole (SXT), Minocycline, Tigecycline, Moxifloxacin, and Ceftazidime Alone and in Combinations for SXT-Susceptible and SXT-Resistant Stenotrophomonas maltophilia by In Vitro Time-Kill Experiments
- (2016) Chuanqi Wei et al. PLoS One
- Adherence to an established diagnostic threshold for ventilator-associated pneumonia contributes to low false-negative rates in trauma patients
- (2015) John P. Sharpe et al. Journal of Trauma and Acute Care Surgery
- Update on infections caused by Stenotrophomonas maltophilia with particular attention to resistance mechanisms and therapeutic options
- (2015) Ya-Ting Chang et al. Frontiers in Microbiology
- Adherence to an established diagnostic threshold for ventilator-associated pneumonia contributes to low false-negative rates in trauma patients
- (2015) John P. Sharpe et al. Journal of Trauma and Acute Care Surgery
- A Monte Carlo pharmacokinetic/pharmacodynamic simulation to evaluate the efficacy of minocycline, tigecycline, moxifloxacin, and levofloxacin in the treatment of hospital-acquired pneumonia caused byStenotrophomonas maltophilia
- (2015) Chuanqi Wei et al. Infectious Diseases
- Tigecycline for Treatment of Nosocomial-Acquired Pneumonia Possibly Caused by Multi-Drug Resistant Strains ofStenotrophomonas maltophilia
- (2014) D. Blanquer et al. JOURNAL OF CHEMOTHERAPY
- Successful Treatment ofStenotrophomonas maltophiliaSoft Tissue Infection with Tigecycline: a Case Report
- (2014) V. Belvisi et al. JOURNAL OF CHEMOTHERAPY
- Resolution of Clinical and Laboratory Abnormalities after Diagnosis of Ventilator-Associated Pneumonia in Trauma Patients
- (2013) Joseph M. Swanson et al. Surgical Infections
- Stenotrophomonas maltophilia: an Emerging Global Opportunistic Pathogen
- (2012) J. S. Brooke CLINICAL MICROBIOLOGY REVIEWS
- Tigecycline as a therapeutic option inStenotrophomonas maltophiliainfections
- (2012) Yasemin Tezer Tekçe et al. JOURNAL OF CHEMOTHERAPY
- Efficacy and safety of tigecycline: a systematic review and meta-analysis
- (2011) Dafna Yahav et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Causative Pathogen Dictates Optimal Duration of Antimicrobial Therapy for Ventilator-Associated Pneumonia in Trauma Patients
- (2011) Louis J. Magnotti et al. JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS
- Clinical and Microbiologic Outcomes in Trauma Patients Treated forStenotrophomonas maltophiliaVentilator-Associated Pneumonia
- (2011) Quinn A Czosnowski et al. PHARMACOTHERAPY
- Treatment of Recurrent Stenotrophomonas maltophilia Ventilator-Associated Pneumonia with Doxycycline and Aerosolized Colistin
- (2010) G. C. Wood et al. ANNALS OF PHARMACOTHERAPY
- Antimicrobial Susceptibilities of a Worldwide Collection of Stenotrophomonas maltophilia Isolates Tested against Tigecycline and Agents Commonly Used for S. maltophilia Infections
- (2010) D. J. Farrell et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Stenotrophomonas maltophilia: an emerging opportunist human pathogen
- (2009) W John Looney et al. LANCET INFECTIOUS DISEASES
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExplorePublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More